Biotech pharma

Serinus Biosciences

Website

Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer

Founded 2022Origin source ↗Checked 2026-09-15

Overview

Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.

Company description As recorded 2026-11-08
LinkedIn
Biotech pharmaAnalyticsBusinessesEnterpriseLicensing

Founders & team

Previously Serinus

Company history As recorded 2026-11-08

Adam Yaari

Founder/CEO

Prior to founding Serinus, Adam gained over 10 years of entrepreneurship experience including a Microsoft R&D Fellowship and Flagship Pioneering Ideation Fellowship. Adam is passionate about developing advanced AI models for biological research that will bring medicine to scale. Adam received his PhD and MS in computer science from MIT, MSc in computer science and mathematics from the Weizmann Institute of Science, and dual major BSc in computer science and neuroscience from Bar-Ilan University.

LinkedIn X
Founder profile As recorded 2026-09-15

Maxwell Sherman

Founder/CTO

After five years as a paramedic, Max left clinical medicine to develop new treatments for the millions of patients without access to effective medications. He studied applied math and biology at Brown University, statistics at Cambridge University, and is completing his PhD in computational biology at MIT. His research has appeared in prestigious journals including Science, Nature Biotechnology, and Nature Neuroscience and has been recognized with national and international awards.

LinkedIn X
Founder profile As recorded 2026-09-15
6team members reported
Source-reported As recorded 2026-09-15

Founded 2022 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedNew York City, NY, USA; New York, NY, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The homepage contains prelaunch or closure language; availability needs review.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year
startup.observe Directory coverage · Sources & method